Vigil Neuroscience is a clinical-stage biotechnology company focused on developing novel therapies for rare and common neurodegenerative diseases by targeting the brain’s immune cells, known as microglia. Its pipeline includes small-molecule and antibody-based programs designed to modulate TREM2 signaling to enhance microglial function and slow neurodegeneration, with lead candidates advancing in clinical studies for conditions such as Alzheimer’s disease and other CNS disorders.

IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.